Tag Archives: Moncef Slaoui

CNBC reports: Moncef Slaoui, who was chief scientist for the U.S government’s Covid vaccine development effort Operation Warp Speed during the Trump administration, was fired as Galvani Bioelectronics chairman over “substantiated” sexual harassment allegations by a woman, it was announced Wednesday. Slaoui’s dismissal by the board of Galvani majority shareholder GlaxoSmithKline came after GSK in February was sent a letter …

The Hill reports: The U.S. is hoping to give a COVID-19 vaccine to 100 million people by the end of February, the head of the administration’s Operation Warp Speed told reporters Wednesday. Moncef Slaoui said that number essentially represents all the nation’s frontline health workers, the elderly, and people with underlying conditions. Slaoui, who was tapped by the Trump administration …

Mediaite reports: Operation Warp Speed chief adviser Dr. Moncef Slaoui downplayed President Donald Trump’s involvement in the coronavirus vaccine breakthroughs on MSNBC, Monday claiming that the president “has never been very actively involved.” Slaoui told Andrea Mitchell that “the vaccine is going to help us get back to some level of normalcy,” noting, “The vaccine will really become effective and …

The Hill reports: The co-director of the White House’s “Operation Warp Speed” will not be required to divest his investments in pharmaceutical companies and will not be subject to federal disclosure rules, according to a decision by a government watchdog. Advocacy groups Public Citizen and Lower Drug Prices Now filed the complaint with the Department of Health and Human Services …

The Hill reports: The former drug company executive leading the Trump administration’s coronavirus vaccine initiative said he will divest all his shares in Moderna, one of the initiative’s leading candidates. At the time of his appointment to lead “Operation Warp Speed,” the shares were worth about $10 million. The announcement comes as Moderna’s stock soared almost 20 percent on Monday, …

CNBC reports: Moderna’s closely watched early-stage human trial for a coronavirus vaccine produced Covid-19 antibodies in all 45 participants, the biotech company announced Monday. Each participant was assigned to receive a 25 microgram, 100 mcg or 250 mcg dose at both vaccinations, with 15 people in each dose group. Study participants received two doses of the potential vaccine via intramuscular …

Politico reports: The former head of GlaxoSmithKline’s vaccine division will serve as the Trump administration’s “therapeutics czar,” working to speed the development of potential coronavirus vaccines, three individuals with knowledge of the selection told POLITICO. Moncef Slaoui, who left the drugmaker in 2017 and has worked as a venture capitalist, will help coordinate the development of Covid-19 vaccines and treatments …